TRCT
CMPX icon

Tower Research Capital (TRC)’s Compass Therapeutics CMPX Stock Holding History

Tower Research Capital (TRC)’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$16.4K Sell
7,474
-15,778
-68% -$46.6K ﹤0.01% 3716
2026
Q1 		$123K Buy
23,252
+21,554
+1,269% +$124K ﹤0.01% 2025
2025
Q4 		$9.12K Sell
1,698
-4,341
-72% -$20K ﹤0.01% 3919
2025
Q3 		$21.1K Sell
6,039
-8,539
-59% -$27K ﹤0.01% 3262
2025
Q2 		$37.9K Sell
14,578
-7,944
-35% -$16.4K ﹤0.01% 3208
2025
Q1 		$42.8K Buy
22,522
+5,271
+31% +$14K ﹤0.01% 2332
2024
Q4 		$25K Buy
17,251
+12,917
+298% +$21.5K ﹤0.01% 3026
2024
Q3 		$7.97K Sell
4,334
-41,683
-91% -$52K ﹤0.01% 3992
2024
Q2 		$46K Buy
46,017
+45,220
+5,674% +$66K ﹤0.01% 3174
2024
Q1 		$1.58K Sell
797
-9,418
-92% -$16.3K ﹤0.01% 5240
2023
Q4 		$15.9K Buy
10,215
+4,077
+66% +$7.05K ﹤0.01% 3800
2023
Q3 		$12.1K Sell
6,138
-576
-9% -$1.42K ﹤0.01% 3925
2023
Q2 		$21.4K Sell
6,714
-1,141
-15% -$3.58K ﹤0.01% 3333
2023
Q1 		$26K Buy
7,855
+6,695
+577% +$26.3K ﹤0.01% 3145
2022
Q4 		$6K Buy
+1,160
New +$4.63K ﹤0.01% 4695
2022
Q1 		– Sell
-3,205
Closed -$10K – 6132
2021
Q4 		$10K Buy
+3,205
New +$10.6K ﹤0.01% 4538

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $345M AUM 134.64% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PAI
Palo Alto Investors Palo Alto, California $724M AUM 96.91% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Tower Research Capital (TRC)'s CMPX Position: Q2 2026 in Review

Tower Research Capital (TRC) reduced its Compass Therapeutics (CMPX) stake by 68% in Q2 2026, selling an estimated $46.6K and leaving 7,474 shares worth $16.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3716.

Tower Research Capital (TRC) first reported a position in CMPX in Q4 2021 and has held it in 16 quarters since. The position peaked at $123K in Q1 2026. 215 funds tracked by Wall St. Rank hold CMPX as of Q2 2026.

  • Tower Research Capital (TRC) held 7,474 shares of Compass Therapeutics worth $16.4K as of Q2 2026.
  • Tower Research Capital (TRC) sold 15,778 Compass Therapeutics shares in Q2 2026, an estimated $46.6K.
  • Compass Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #3716 holding.
  • Tower Research Capital (TRC) first reported a position in Compass Therapeutics in Q4 2021 and has held it in 16 quarters since.
  • Tower Research Capital (TRC)'s Compass Therapeutics position peaked at $123K in Q1 2026.
  • 215 funds tracked by Wall St. Rank held Compass Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.